(Total Views: 348)
Posted On: 01/05/2021 10:31:37 PM
Post# of 36568
Interesting point tc.
For the record, I have communicated with Chris Reinhard of Gene Biotherapeutics for quite some time. GB is the newer name for Taxus Cardium(CRXM) Chris confirmed some time back Olaregen, now Generex does owe GB $3.5 million. I did not think to ask at the time if that was actually owed or being accrued based on sales. If it is based on sales then great except of we would all like the revenue for GNBT. I didn’t get the impression Chris was worried about as they recently got a investment from a pharma company and are about to come back to life much like Joe did with Generex in 2017. Sorry if I confused anyone about the $3.5 million.
For the record, I have communicated with Chris Reinhard of Gene Biotherapeutics for quite some time. GB is the newer name for Taxus Cardium(CRXM) Chris confirmed some time back Olaregen, now Generex does owe GB $3.5 million. I did not think to ask at the time if that was actually owed or being accrued based on sales. If it is based on sales then great except of we would all like the revenue for GNBT. I didn’t get the impression Chris was worried about as they recently got a investment from a pharma company and are about to come back to life much like Joe did with Generex in 2017. Sorry if I confused anyone about the $3.5 million.
(2)
(0)
